Selling Your Veterinary Practice to Community Veterinary Partners: A Vet’s 2026 Guide

Key takeaways

• Community Veterinary Partners (CVP) is a private equity-backed veterinary consolidator headquartered in Philadelphia, Pennsylvania, founded in 2009, with a hospital network concentrated in the Northeast and Mid-Atlantic United States.
• OMERS Private Equity is the current owner per public ownership disclosures, the investment arm of one of Canada’s largest defined-benefit pension plans, which means a longer hold horizon than a conventional PE fund cycle.
• Regional density is CVP’s defining strategy. The platform tends to pursue practices that build clustering inside markets where it already operates, which can make CVP an especially motivated bidder for a practice that sits inside its core Northeast and Mid-Atlantic geography.
• The pension-fund hold horizon changes the rollover-equity math. A long-hold owner is not bound to a 5-to-7-year fund clock, so the timing and probability picture around a future liquidity event differ from a standard PE-fund platform. That is the single most important CVP-specific dimension for any seller weighing rollover equity.
• The most reliable way to know what CVP, or any major buyer, would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. CVP is invited inside that rope on practices that fit their regional criteria, and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

When a vet hands me an offer from Community Veterinary Partners, the first thing I want to know is where the practice sits on a map. With most buyers that question is secondary.

With CVP it is close to the center of the whole conversation, because CVP’s strategy is built around regional density more visibly than almost any other buyer in the pool.

The owners I talk to usually sense this without having the language for it. A vet in eastern Pennsylvania or upstate New York will tell me CVP “seems really interested,” and they’re right to read that as a signal.

A practice that fills in a gap inside CVP’s existing cluster is worth more to CVP than the same practice would be to a buyer with no presence nearby. That regional logic shapes the whole deal.

The second thing I want the owner to understand is who actually owns CVP now, because the answer changes how I’d think about one specific part of the offer. CVP is owned by OMERS Private Equity, the investment arm of a Canadian pension plan, per public ownership disclosures.

A pension fund holds for longer than a conventional private equity fund does, and that hold horizon reaches directly into the rollover-equity decision.

What follows is the same picture I’d lay out over dinner if a vet handed me a CVP offer and asked what to do with it. Who CVP is, how the regional-density strategy shapes what they’ll pay, what a pension-fund owner means for hold horizon and rollover equity, where the negotiation leverage actually sits, and how to think about CVP against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on Community Veterinary Partners

Community Veterinary Partners is a private equity-backed veterinary practice consolidator headquartered in Philadelphia, Pennsylvania. The platform was founded in 2009 and has grown a multi-state hospital network over more than 15 years.

CVP’s footprint is concentrated in the Northeast and Mid-Atlantic United States, with hospitals across states including Pennsylvania, New York, New Jersey, Connecticut, Massachusetts, Maryland, and Virginia, plus additional locations reaching into the Southeast and Midwest per CVP company materials. The network spans general practice, specialty, and emergency hospitals.

The ownership matters as much as the geography for a seller evaluating CVP. The platform is currently owned by OMERS Private Equity, the private equity arm of OMERS, one of Canada’s largest defined-benefit pension plans.

OMERS acquired CVP from Cortec Group in 2019; Cortec, a New York-based middle-market private equity firm, had owned the platform during an earlier growth chapter.

The single most important structural fact for a seller. A pension-fund sponsor typically holds longer than a conventional PE fund. A standard private equity fund runs on a defined cycle, often 5 to 7 years, before it must sell its portfolio companies and return capital to its own investors. A pension plan’s capital is patient by design, which gives a platform like CVP more flexibility on the timing of its next ownership transition.

That difference reaches directly into the rollover-equity question, which we’ll come back to in depth.

What CVP actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer’s acquisition team, CVP included, the offer reflects the leverage the buyer perceives in the room. A single bidder facing no visible competition has no structural reason to lead with their strongest cash percentage, their tightest earnout protections, or their most flexible clinical-autonomy language.

Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully. This is not unique to CVP.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room.

There is a CVP-specific wrinkle worth naming, though. Because CVP’s strategy leans so heavily on regional density, a practice that fills a gap inside CVP’s existing cluster can be worth more to CVP than to a buyer with no nearby presence.

That strategic fit is a source of leverage for the seller, but only if the seller surfaces it. A practice owner who doesn’t know they sit inside a market CVP wants to deepen has no way to price that value into the conversation.

CVP does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

EBITDA here means what your practice earns in pure operating profit, before taxes and accounting choices, and the multiple is the multiplier buyers apply to that profit to set the price.

The actual number for any specific practice depends heavily on whether other qualified buyers are at the table and on the practice’s fit with CVP’s regional footprint. CVP participates in this competitive band when it bids on qualifying practices, with the specific offer on any specific deal negotiated case by case under confidentiality.

For specialty and emergency hospitals, the broader market generally values these higher than comparable general practices per industry research. CVP operates specialty and emergency hospitals within its network and may bid for qualifying specialty platforms when they fit the geographic and operational criteria.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward smaller regional groups and individual buyers. CVP’s historical focus has tilted toward established multi-doctor practices that strengthen the density of its existing regional clusters.

The cash-at-close reality

For a platform backed by a pension-fund sponsor, the cash-at-close component of any offer is unlikely to be the dimension where CVP underperforms competitive expectations. Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), the typical offer structure allocates the majority of total deal value to cash at close, with the remainder split among earnout, rollover or partnership equity, and occasional seller notes.

CVP’s specific allocation on any given deal is negotiated case by case.

Where the pension-fund ownership shows up most directly is not in the cash percentage but in the retained-equity picture. A long-hold sponsor changes the underlying timing assumptions a seller should bring to a rollover decision, which is a different conversation from the cash-at-close split.

We’ll work through that in the rollover section below.

For now, the practical point is simple. Push for the highest cash-at-close percentage the competitive process will support, because every dollar shifted from contingent to cash at close is guaranteed money rather than money that depends on future performance.

A buyer backed by patient pension capital generally has the balance-sheet flexibility to be competitive on this dimension when other qualified bidders are in the room.

A note on deal structure types in the current market

The broader US veterinary M&A market has shifted measurably toward partnership and joint-venture structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. In these structures, the buyer acquires a majority stake, commonly 60 to 80 percent, the seller retains a minority stake, commonly 20 to 40 percent, as direct equity in the practice itself, and a contractual put/call mechanism defines the buyout date and formula price for the retained equity.

AmeriVet, Rarebreed Veterinary Partners, and the legacy SVP playbook now inside Mission Pet Health have publicly emphasized partnership variants in their company materials.

CVP’s specific posture on partnership versus 100-percent acquisition structures is determined case by case under confidentiality and is not publicly enumerated. What can be said with confidence is that a long-hold pension-fund sponsor and a partnership or rollover structure interact in a way worth understanding.

The value of a retained stake depends in part on when the next liquidity event arrives, and a patient owner is under less pressure to force that event on a fund’s clock.

Sellers evaluating a CVP offer should ask explicitly whether a partnership structure is available alongside the more traditional 100-percent acquisition with rollover equity. Our PE pricing guide covers the structure-by-structure comparison in depth.

How CVP’s acquisition team operates

CVP’s corporate-development function is built around the regional-density thesis that defines the platform. The team’s sourcing has historically emphasized practices in and around markets where CVP already operates per CVP company materials, because clinical referral networks, back-office cost-sharing, recruiting reach, and operational support are all easier to deliver when a new acquisition sits inside an existing CVP regional cluster.

The team works the standard mix of sourcing channels: direct outreach to owners identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners reaching out independently.

A practical implication for sellers. If your practice sits inside or adjacent to one of CVP’s core markets, you are likely a higher-priority target than your revenue alone would suggest, and that strategic value is a negotiating asset.

But it is only an asset if you know to use it. The way to surface and price that value is to put CVP into a competitive process where the platform has to express how much your geographic fit is actually worth to it, rather than learning that only after you’ve already signed.

That isn’t unique to CVP. The same logic holds across the institutional buyer pool.

But the regional-density emphasis makes the geographic-fit lever sharper with CVP than the seller might assume from the platform’s measured outward posture.

How CVP integrates the practices it acquires

CVP’s integration model pairs operational support with local-identity preservation. The platform absorbs the back-office work while leaving the customer-facing practice recognizable to the clients who already trust it.

Local identity preservation. Per CVP company materials, CVP’s general approach is to preserve the practice name, signage, and local identity while providing operational support behind the scenes. The integration focuses on back-office and operational dimensions rather than brand consolidation.

This is one of the dimensions where CVP differs structurally from Mars-affiliated entities, which more commonly transition acquired practices to a Mars-network brand over time.

Regional shared services. Per CVP company materials, the platform provides centralized support functions, including HR, accounting, payroll, recruiting, marketing infrastructure, and operational systems, organized around its regional clusters. The density of the network is what makes those shared services efficient to deliver, which is the operational payoff of the regional-density strategy.

Centralized procurement. Platform scale translates into purchasing leverage that an independent practice cannot match on its own. CVP’s negotiated vendor contracts for diagnostics, pharmaceuticals, equipment, and supplies typically reduce variable costs across the practice’s P&L compared to the independent baseline.

The earnout implication runs both directions. Lower input costs can raise practice-level EBITDA, which supports the earnout, but central procurement decisions that override seller preferences need protective language in the deal.

Recruiting and staffing support. A dense regional network gives CVP recruiting reach that a standalone practice rarely has, which is one of the support dimensions sellers commonly cite as a benefit, particularly in tight veterinary labor markets across the Northeast.

Doctor relationships. Per industry M&A commentary on PE-backed veterinary acquirers, selling owners commonly stay on as medical director or in a continuing clinical role for a multi-year post-close period, typically 3 to 5 years, with compensation structured as base salary plus production bonus. CVP’s specific post-sale employment terms for any given deal are negotiated case by case under the definitive purchase agreement.

CVP’s recent activity in 2025-2026

CVP enters 2026 as an established, regionally focused acquirer in the US veterinary buyer pool. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration heading into 2026, with both PE-backed and strategic acquirers running active pipelines.

CVP-attributable activity in trade press and Octus’s 2025-2026 sector coverage suggests a cadence consistent with the platform’s regional-clustering strategy, though specific acquisition counts are not publicly itemized by CVP in real time.

The practical takeaway for an owner receiving 2026 CVP outreach: this is a buyer running a sustained, geographically deliberate acquisition program backed by patient pension capital. The implications of that combination, the regional-fit value on one side and the long-hold rollover dynamics on the other, are the lens through which the offer in your hand should be evaluated.

Have an offer from Community Veterinary Partners? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How CVP compares to the other major buyers

If you’re considering CVP, you’re probably comparing them implicitly to the other major buyers who would compete for your practice. Here’s how CVP stacks up across the dimensions that matter.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the US veterinary buyer pool per Mars company disclosures, distinguishing it from CVP’s PE-backed structure. The brand-handling difference is significant.

CVP’s local-identity-preservation approach contrasts with VCA’s historical brand-consolidation pattern under the VCA name. Both Mars-affiliated entities and CVP may compete for qualifying practices in a structured sale process.

Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus NVA (JAB Holdings). This is the most instructive comparison for the through-line. NVA is owned by JAB Holdings, a privately held long-hold investment vehicle, and CVP is owned by OMERS, a pension fund.

Both sponsors operate on longer horizons than a conventional PE fund, which means both platforms can offer rollover-equity structures that aren’t bound to a tight fund clock. The practical differences come down to footprint and specific terms rather than ownership philosophy.

Our NVA buyer profile walks through the NVA-specific dimensions.

Versus VetCor (Harvest Partners). VetCor is one of the longest-tenured PE-backed platforms and overlaps with CVP across parts of the Northeast. The key contrast is ownership type.

VetCor sits inside a conventional PE-fund structure, while CVP’s pension-fund sponsor brings a longer hold horizon. Both preserve local practice identity per their respective company materials.

Our VetCor buyer profile covers the longevity dimensions.

Versus AmeriVet Veterinary Partners. AmeriVet has publicly emphasized partnership and JV structures as a distinguishing feature, while CVP’s standard posture has historically leaned toward acquisition with rollover equity. Both preserve local identity per their respective company materials.

The choice often comes down to whether the seller prefers a partnership structure with retained practice-level equity or a rollover into a pension-fund-backed platform. Our AmeriVet buyer profile covers the partnership-model dimensions.

Versus Mission Pet Health and PetVet Care Centers. Mission Pet Health, the post-merger entity formed from SVP and MVP per the 2025 Mission Pet Health press release, and PetVet Care Centers, backed by KKR per PetVet company materials, are both mature PE-backed platforms that may compete for qualifying practices. Each has its own footprint and integration philosophy, and the right way to weigh them against CVP is head-to-head in a competitive process.

Versus the smaller PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Heartland, VPP, others). Each has its own integration philosophy and target profile. Smaller and newer groups sometimes pay more aggressively for practices that fill specific geographic or specialty gaps in their portfolio.

The right way to evaluate which buyer pays most is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with CVP

Six priorities when negotiating with CVP’s acquisition team, with the rollover-equity terms and earnout protective provisions as the highest-leverage categories given the pension-fund ownership and the regional-density operating model.

Rollover equity terms (highest priority given the long-hold sponsor). If CVP’s offer includes rollover, the pension-fund hold horizon changes the timing assumptions you should bring to the decision. Rollover equity means keeping a slice of ownership in the new entity instead of taking all cash at close, and its value depends heavily on when the next liquidity event arrives.

With a patient owner, that event isn’t forced by a fund clock, which can be an advantage, but you should still negotiate the standard protections: defined liquidity windows or put/call rights tied to specific dates and a transparent formula price, governance rights including information rights and minority protection clauses, and anti-dilution provisions. Ask explicitly how the put/call window works under a long-hold sponsor.

Earnout protective provisions. CVP’s regional-density model involves shared central services and centralized procurement that can shift practice-level EBITDA in either direction during the earnout window. The protective provisions to negotiate: no major operational changes without seller consent during the earnout period; a working capital floor; an explicit prohibition on shifting central services costs from other CVP practices to the seller’s practice; and a clear definition of what counts in the EBITDA calculation at the earnout date.

Cash at close percentage. Push for higher cash percentages. Every dollar shifted from contingent to cash is guaranteed money instead of conditional.

A pension-fund-backed buyer generally has the balance-sheet flexibility to be competitive on this dimension when the process is competitive.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. Negotiate: shorter duration of 1 to 2 years, a tighter radius of 5 to 10 miles, or a carve-out for a specific specialty or modality if you might continue clinical work post-employment.

Post-sale clinical autonomy. CVP’s regional operating structure includes operational standards and shared systems delivered across the cluster. Negotiate explicit language preserving your clinical autonomy, meaning you make medicine decisions, not the regional team, and a clear definition of which business decisions stay with you versus migrating to CVP’s regional structure.

Local-identity preservation in writing. CVP’s company materials emphasize preserving local practice identity, and the historical pattern supports that posture. But marketing language is not the same as a contractual commitment.

Negotiate explicit identity-preservation language in the definitive purchase agreement, covering practice name, signage, website, and marketing materials, even though it aligns with CVP’s stated philosophy.

The pension-fund hold horizon and rollover equity, in depth

For sellers evaluating CVP specifically, the most useful frame is to think carefully about what a pension-fund owner means for the post-sale equity decision. This is the dimension where CVP’s ownership genuinely differs from a conventional PE-fund platform, and it deserves real attention.

Why the hold horizon matters. A conventional private equity fund runs on a defined cycle. The fund raises capital, deploys it, holds for roughly 5 to 7 years, then must sell its portfolio companies and return capital to its own investors.

That clock creates pressure to engineer a liquidity event on a schedule. A pension plan’s capital is patient by design, because the plan’s obligation is to pay retirees over decades, not to return capital to limited partners on a fund timetable.

A platform owned by a pension fund therefore has more flexibility on the timing of its next ownership transition.

What that means for rollover equity. When a seller rolls over equity, meaning they keep a minority slice of ownership in the combined entity rather than taking all cash, the value of that slice depends on two things: the price at the eventual exit and the timing of that exit. Under a long-hold sponsor:

• The next liquidity event is less tightly bound to a fund’s clock, so the timing is less predictable in one sense but less rushed in another
• A patient owner is under less pressure to force a sale at a moment that maximizes the fund’s return rather than the practice’s long-term value
• The seller’s retained stake can compound over a longer runway if the platform continues to grow before the next transition
• The flip side: a longer or less-defined hold can mean the seller waits longer for liquidity on the retained portion, which is exactly why the put/call mechanics matter

The negotiation consequence. Because the hold horizon is genuinely different, the rollover terms deserve more scrutiny with CVP than a seller might give a standard PE-fund platform. The questions to press: How does the put/call window work?

Is there a defined date at which the seller can require a buyout of the retained stake, and at what formula price? What information rights does the seller have during the hold?

These are the terms that determine whether a long-hold structure works in the seller’s favor or simply means a longer wait for the rest of the money.

The balance between these dimensions is exactly what gets negotiated in the definitive purchase agreement. Sellers who go into the conversation with a refined sell-side process, and other qualified bidders at the table, consistently land more favorable positions than sellers who engage in a one-on-one conversation.

Should I take a CVP offer or run a competitive process?

For CVP specifically, the value of the competitive process concentrates in two places: pricing the regional-fit value that CVP places on a practice inside its cluster, and getting the rollover-equity terms right under a long-hold sponsor. The headline cash percentage is unlikely to move dramatically on its own, because a pension-fund-backed buyer generally supports competitive cash-at-close numbers.

Where the process produces leverage is on the dimensions that interact with CVP’s strategy and ownership: the geographic-fit premium, the rollover put/call mechanics, the earnout protective clauses, and the local-identity guarantees.

The mechanical reason is the same as for any major buyer. Without competition, no buyer has incentive to lead with their strongest terms or to fully price the strategic value of a practice that fits their footprint.

With competition, every term becomes negotiable because every bidder knows the seller has alternatives. For a platform whose strategy depends so heavily on regional density, the strategic-fit value of the right practice can be substantial, and the only reliable way to surface it is to make CVP express it against other bidders.

CVP participates in well-run competitive processes when invited. The CVP-specific dimensions, the regional-fit premium, the rollover terms under a long-hold sponsor, the earnout protective provisions, get sharper attention from the CVP team when they know other qualified buyers are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a CVP-affiliated transaction, our process runs with two CVP-specific emphases: surfacing the regional-fit value and structuring the rollover correctly for a long-hold owner.

Phase one, the strategic-fit and structure audit. Before any bidder packet goes out, we map where the practice sits relative to CVP’s existing regional clusters and assess how much strategic value the geography likely carries. We also model the rollover question against a pension-fund hold horizon, because the timing assumptions differ from a conventional fund.

This audit identifies the leverage points, the geographic premium and the rollover mechanics, before the competitive process opens.

Phase two, the bidder mix. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones that legitimately compete with CVP for this specific practice. The other long-hold buyers (NVA under JAB) compete on hold horizon.

The regionally overlapping platforms (VetCor and others active in the Northeast) compete on density. The partnership-emphasis buyers (AmeriVet, Mission Pet Health, Rarebreed) compete on structure flexibility.

The strategic family-owned alternative (Mars, where the practice fits Mars’s criteria) competes on a different axis entirely. The right mix is typically 5 to 7 invited bidders, each genuinely competing on a dimension CVP cares about.

Phase three, the term-by-term comparison. Bidders return their full term sheets, not just the headline numbers. The seller sees side-by-side comparisons across cash-at-close, earnout structure and protective provisions, rollover or partnership equity terms including put/call mechanics, non-compete scope, post-sale role, local-identity commitments, and integration roadmap.

The seller chooses on the dimensions that matter, sometimes the platform with the strongest regional fit (CVP), sometimes the platform with the most favorable rollover terms, sometimes the platform with the highest headline number.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes, typically multiple seven figures, sometimes more, than the same practice would have cleared by signing the original direct CVP term sheet without exploring the field.

Closing thought

The honest read on CVP: it is a serious, regionally focused acquirer with a clear strategy and a patient owner. Sellers whose practices sit inside CVP’s Northeast and Mid-Atlantic footprint should take CVP’s interest as a real signal, and they should understand that the platform’s regional-density thesis can make the right practice genuinely more valuable to CVP than to a buyer with no nearby presence.

What separates a well-negotiated CVP outcome from a mediocre one is rarely the cash multiple alone. It’s whether the seller priced the regional-fit value and got the rollover terms right under a long-hold pension-fund sponsor.

Those dimensions, the geographic premium and the put/call mechanics on retained equity, determine whether CVP’s ownership structure works in the seller’s favor or simply means a longer wait for the rest of the money.

If you’ve received a CVP offer, or if CVP’s acquisition team has reached out to start the conversation, the highest-leverage move is to understand how the rest of the field would value and structure the same practice before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same regional-fit and rollover comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Community Veterinary Partners and parent company materials

6. Community Veterinary Partners. About CVP and US network footprint. CVP company materials, cvpco.com, 2024-2026.
7. OMERS Private Equity. Community Veterinary Partners investment. OMERS Private Equity portfolio disclosures, omersprivateequity.com.
8. Cortec Group. Announcement of sale of Community Veterinary Partners to OMERS Private Equity. Cortec Group company materials, cortecgroup.com.

Veterinary practice operations, benchmarks, and profession data

9. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
10. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.